Takeda Pharmaceutical
4502.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥591.6bn | ¥580.4bn | ¥595.6bn | ¥632.1bn | ¥764.3bn | ¥602.6bn |
| Operating income | ¥21.1bn | ¥36.9bn | ¥48.1bn | ¥136.1bn | ¥293.7bn | ¥121.1bn |
| Ordinary income | ¥205.5bn | ¥86.6bn | ¥286.4bn | ¥340.1bn | ¥550.9bn | ¥50.0bn |
| Total assets | ¥9.64T | ¥9.49T | ¥9.76T | ¥9.41T | ¥9.64T | ¥10.86T |
| Net assets / equity | ¥3.76T | ¥3.99T | ¥4.09T | ¥4.21T | ¥4.29T | ¥4.43T |
| EPS (basic) | ¥125.29 | ¥96.79 | ¥216.6 | ¥213.06 | ¥207.5 | ¥158.45 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 213 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 82 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 213 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 213 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 106 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 213 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 106 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 82 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 213 figures · EDINET |
21 more reports are still being processed.